• Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

    Источник: Nasdaq GlobeNewswire / 09 апр 2024 08:00:00   America/New_York

    N/A
Опубликовать